A5059616261- Parkinson's Disease Mechanisms and Treatments
- Neuroscience and Neuropharmacology Research
- Nerve injury and regeneration
- Neurological disorders and treatments
- Autism Spectrum Disorder Research
- Pharmacological Receptor Mechanisms and Effects
- Neurotransmitter Receptor Influence on Behavior
- SARS-CoV-2 and COVID-19 Research
- Cholinesterase and Neurodegenerative Diseases
- Inhalation and Respiratory Drug Delivery
- Neuroinflammation and Neurodegeneration Mechanisms
- Receptor Mechanisms and Signaling
- biodegradable polymer synthesis and properties
- Virus-based gene therapy research
- Allergic Rhinitis and Sensitization
- Neurological diseases and metabolism
- Neurogenesis and neuroplasticity mechanisms
- Barrier Structure and Function Studies
- Olfactory and Sensory Function Studies
- Diet and metabolism studies
- Asthma and respiratory diseases
- Nuclear Receptors and Signaling
- Mitochondrial Function and Pathology
- Acute Ischemic Stroke Management
- Ion channel regulation and function
Lund University
2010-2024
University of Trieste
2019
Skåne University Hospital
2016
The Memory Clinic
2015
University College London
2015
Banner Sun Health Research Institute
2015
Mayo Clinic in Arizona
2015
The sigma-1 receptor, an endoplasmic reticulum-associated molecular chaperone, is attracting great interest as a potential target for neuroprotective treatments. We provide the first evidence that pharmacological modulation of this protein produces functional neurorestoration in experimental parkinsonism. Mice with intrastriatal 6-hydroxydopamine lesions were treated daily selective receptor agonist, PRE-084, 5 weeks. At dose 0.3 mg/kg/day, PRE-084 produced gradual and significant...
l -dopa–induced dyskinesia (LID) is a common debilitating complication of dopamine replacement therapy in Parkinson's disease. Recent evidence suggests that LID may be linked causally to hyperactivation the Ras–ERK signaling cascade basal ganglia. We set out determine whether specific targeting Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1), brain-specific activator pathway, provide for LID. On rodent abnormal involuntary movements scale, Ras-GRF1–deficient mice were significantly...
To study biomarkers of angiogenesis in Parkinson disease (PD), and how these are associated with clinical characteristics, blood-brain barrier (BBB) permeability, cerebrovascular disease.In this cross-sectional analysis, 38 elderly controls 100 patients PD (82 without dementia 18 dementia) were included from the prospective Swedish BioFinder study. CSF samples analyzed for vascular endothelial growth factor (VEGF); its receptors, VEGFR-1 VEGFR-2; placental (PlGF); angiopoietin 2 (Ang2);...
Angiogenesis and increased permeability of the blood–brain barrier have been reported to occur in animal models Parkinson's disease l-dopa-induced dyskinesia, but significance these phenomena has remained unclear. Using a validated rat model this study demonstrates that chronic treatment with l-dopa dose dependently induces expression vascular endothelial growth factor basal ganglia nuclei. Vascular was abundantly expressed astrocytes astrocytic processes proximity blood vessels. When...
Significance Parkinson's disease is characterized by a set of motor features that depend on loss dopamine-producing cells in the midbrain. The most common pharmacotherapy for dopamine replacement with levodopa administration. majority patients receiving this treatment develop debilitating abnormal involuntary movements, termed “levodopa-induced dyskinesia.” It known striatal projection neurons (SPNs) are involved genesis levodopa-induced dyskinesia, but genes process not fully understood. We...
Pridopidine is a small molecule in clinical development for the treatment of Huntington's disease. It was recently found to have high binding affinity sigma-1 receptor, chaperone protein involved cellular defense mechanisms and neuroplasticity. Here, we evaluated neuroprotective neurorestorative effects pridopidine unilateral 6-hydroxydopamine (6-OHDA) lesion model parkinsonism mice. By 5 weeks daily administration, low dose (0.3 mg/kg) had significantly improved deficits forelimb use...
Chronic levodopa treatment leads to the appearance of dyskinesia in majority Parkinson's disease patients. Neurovascular dysregulation putaminal and pallidal regions is thought be an underlying feature this complication treatment. We used microPET study unilaterally lesioned 6-hydroxydopamine rats that developed levodopa-induced abnormal involuntary movements (AIMs) after three weeks drug Animals were scanned with [15O]-labeled water [18F]-fluorodeoxyglucose, map regional cerebral blood flow...
The nasal epithelium is a key portal for infection by respiratory viruses such as SARS-CoV-2 and represents an important target prophylactic therapeutic interventions. In the present study, we test safety efficacy of newly developed spray (AM-301, marketed Bentrio) against its Delta variant on in vitro 3D-model primary human airway epithelium. Safety was assessed assays tight junction integrity, cytotoxicity cilia beating frequency. Efficacy evaluated pre-viral load post-viral application No...
Significance Medications for Parkinson’s disease (PD) are designed to replace lost dopamine. Although effective, they often cause abnormal involuntary movements (AIMs), also called dyskinesias, which can be difficult resolve without worsening PD symptoms. We report that p11, a small protein necessary neurotransmitter receptor function, is critical dopamine responses in mouse model. Blocking p11 production the dorsal striatum, brain region responds and regulates movement, improve forced...
Parkinson's disease (PD) is an age-related neurodegenerative disorder characterized by typical motor signs and symptoms that are due to dopamine (DA) depletion in the basal ganglia. The treatment of PD symptomatic, aims at replacing lost DA input using either L-DOPA or agonists. causes unknown approximately 90% cases, whereas about 10% cases familial imputable mutations a handful genes (the gene with strongest association shown Table 1; for detailed review see (Poulopoulos et al., 2012))....
Abstract Levodopa-induced dyskinesia (LID) is a debilitating complication of symptomatic therapy in Parkinson’s disease (PD). Although there compelling evidence that striatal pathophysiology major driver LID, the circuit-specific mechanisms contributing to dysfunction remain obscure. This lack clarity reflected limited options for diminishing established LID. To address this gap, molecular, cellular, and behavioral strategies were used interrogate indirect pathway spiny projection neurons...
Glial cell line-derived neurotrophic factor (GDNF) is the most promising neurotrophin for restorative treatments in Parkinson's disease, but its biological effects are not completely understood.To define a model of GDNF gene therapy mouse, we studied long-term lentiviral delivery mice with striatal 6-hydroxydopamine (6-OHDA) lesions.Lentiviral vectors coding or green fluorescent protein (GFP) were injected unilaterally striatum two weeks prior to 6-OHDA lesion. Mice monitored on tests...
Abstract Plastic changes have been reported in the SOD1‐G93A mouse model of amyotrophic lateral sclerosis, a disorder characterized by progressive motoneuronal loss; however, whether these related with onset and development motor impairments is still unclear. Here, functional anatomical taking place mice their time course were investigated during ongoing degeneration. Starting from about 4 postnatal weeks, wild‐type (WT) evaluated rotarod test, to be sacrificed at 12–13 or 19 weeks age,...